What is the history of Dermatomyositis and Polymyositis?

Dermatomyositis and polymyositis were first clinically identified in the mid-19th century, with dermatomyositis formally described by Ernst Leberecht Wagner in 1863. Over the last 160 years, our understanding has shifted from viewing these as simple muscle-wasting disorders to recognizing them as complex, systemic autoimmune conditions driven by immune system dysregulation and specific genetic markers.

When and how were dermatomyositis and polymyositis first described?

The medical history of dermatomyositis began in 1863 when Ernst Leberecht Wagner described a patient with muscle weakness and a characteristic skin rash, which he termed "polymyositis gravis." Shortly after, in 1887, the term "dermatomyositis" was coined by Heinrich Unverricht to emphasize the dual involvement of the skin and muscles. Polymyositis was historically grouped with these conditions but was later characterized as a distinct clinical entity where muscle inflammation occurs without the hallmark skin changes seen in dermatomyositis.

How has our understanding of these conditions evolved?

For decades, clinicians categorized these diseases primarily by their outward physical symptoms. However, the 20th century brought a shift toward immunology. Researchers began to understand that dermatomyositis and polymyositis are not merely "muscle diseases" but systemic inflammatory processes. In the 1970s, the development of the Bohan and Peter criteria provided the first standardized framework for diagnosis, which remains a cornerstone in clinical practice today. More recently, the identification of myositis-specific antibodies (MSAs) has revolutionized the field, allowing physicians to classify patients into distinct subgroups with predictable clinical courses and organ-system risks.

What were the major milestones in treatment development?

The evolution of treatment has been a journey from palliative care to targeted immunotherapy. Key milestones include:

• 1950s: The introduction of corticosteroids, such as prednisone, which became the first effective therapy to suppress the systemic inflammation associated with dermatomyositis and polymyositis.


• 1970s–1980s: The adoption of steroid-sparing immunosuppressants like methotrexate and azathioprine to reduce the long-term side effects of high-dose steroids.


• 1990s–Present: The integration of intravenous immunoglobulin (IVIG) and advanced biologic therapies, such as rituximab, which target specific immune cells involved in the disease process.

How have modern genetics and technology changed our perspective?

Modern genomics has fundamentally changed how we view the risk factors for dermatomyositis and polymyositis. We now know that these conditions are polygenic, meaning they arise from a combination of genetic susceptibility—particularly within the Human Leukocyte Antigen (HLA) region—and environmental triggers. Technologies like next-generation sequencing and high-resolution proteomics have allowed researchers to identify biomarkers that predict whether a patient is at higher risk for interstitial lung disease or malignancy, moving the field toward a "personalized medicine" approach.

How has patient advocacy shaped the community?

In the early 20th century, patients with dermatomyositis and polymyositis often faced isolation due to the rarity and unpredictable nature of their symptoms. Today, the landscape has shifted toward empowered patient advocacy. Platforms like DiseaseMaps.org, which currently supports 413 community members, have been vital in connecting patients globally. By pooling lived experience, the community has accelerated awareness, helped refine diagnostic criteria through patient-reported outcomes, and pushed for more inclusive clinical trials.

Next steps

• Consult a board-certified rheumatologist or neuromuscular specialist to discuss your specific antibody profile.


• Join the DiseaseMaps.org community to share experiences and find support from others living with dermatomyositis and polymyositis.


• Monitor the latest clinical trials via the NIH ClinicalTrials.gov database to stay informed about emerging therapies.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Dermatomyositis and Polymyositis resources.


• Orphanet: Rare disease database for inflammatory myopathies.


• OMIM (Online Mendelian Inheritance in Man): Genetic data on autoimmune muscle disorders.


• The Myositis Association: Historical perspectives and patient support resources.